Azor
Product Images NDC 54868-6250

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Azor (NDC 54868-6250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 5 mg/ 20 mg Package Label (6036)

Packaging label for Azor 5/20 MG tablets from Physicians Total Care, Inc. The label displays the product name Azor with a strength of 5/20 MG, lot number 0000, and expiration date 01/00. It includes a barcode and identifier code PDN-570-N7440.*

FDA Label Image

Image Of 10 mg/ 40 mg Package Label (6250)

Packaging label for Azor 10/40 mg tablets, distributed by Physicians Total Care, Inc., showing the NDC 54868-6250-0 and a quantity of 38 tablets. The label includes a lot number and an expiration date, manufactured by Daiichi Sankyo, Inc., Parsippany, NJ. A barcode is also present on the label.*

FDA Label Image

Image Of Structural Formula For Amlodipine Besylate (Chemical Structure 01)

Chemical structure diagram showing the molecular composition of Azor, including its active chemical components and their arrangement, accompanied by an additional molecular structure likely representing a related compound or salt.*

FDA Label Image

Image Of Structural Formula For Olmesartan Medoxomil (Chemical Structure 02)

Chemical structure diagram of the active ingredient in Azor, showing the detailed molecular arrangement and bonds between atoms.*

FDA Label Image

Image Of Figure 1 (Figure 1)

A line graph comparing the percentage of patients with systolic blood pressure (SBP) less than 140 mmHg across different baseline SBP values (140-180 mmHg). The graph includes four treatment groups: Placebo, AM1 10 mg, OM40 mg, and Azor 10/40 mg, showing the effectiveness of these treatments in lowering SBP.*

FDA Label Image

Image Of Figure 2 (Figure 2)

A line graph comparing diastolic blood pressure (DBP) in mmHg on the x-axis to the percentage of patients with DBP ≥ 90 mmHg on the y-axis. It shows four treatment groups, including Placebo, Amlodipine 10 mg, Olmesartan Medoxomil (OM) 40 mg, and Azor 10/10 mg. The graph illustrates the effects of these treatments on DBP over a range from 95 to 110 mmHg.*

FDA Label Image

Image Of Figure 3 (Figure 3)

A line graph comparing the percentage of patients with systolic blood pressure (SBP) less than 130 mmHg versus baseline SBP (mmHg) among four groups: Placebo, Olmesartan Medoxomil 40 mg, Amlodipine 10 mg, and Azor 10/40 mg. Azor demonstrates the highest percentage of patients achieving SBP <130 mmHg across baseline SBP values from 140 to 180 mmHg.*

FDA Label Image

Image Of Figure 4 (Figure 4)

A line graph comparing the percentage of patients with diastolic blood pressure (DBP) greater than or equal to 80 mmHg across different baseline DBP values (95 to 110 mmHg). Four lines represent Placebo, Olmesartan Medoxomil 40 mg, Amlodipine 10 mg, and Azor 10/40 mg, with Azor showing the highest percentage reduction in DBP ≥ 80 mmHg over the baseline range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.